Breaking News, Financial News

Financial Report: Charles River Laboratories 2Q

Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Charles River Laboratories

2Q Revenues: $308.2 million (-13%)

2Q Earnings: $34.2 million (-30%)

FY Revenues: $609.7 million (-12%)

FY Earnings: $59.6 million (-36%)

Comments: Sales declined in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments, reflecting the negative impact of foreign exchange, as well as softer market demand. RMS sales were $165.7 million in the quarter (-4%) and PCS segment sales were $142.5 million (-21%).

Sign up today for Contracting & Outsourcing 2009!


Keep Up With Our Content. Subscribe To Contract Pharma Newsletters